Trial reportBritish journal of clinical pharmacology2004
Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.
Trial report in British journal of clinical pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 69 citations in OpenAlex.
- OATP1B1 polymorphism as a determinant of erythromycin disposition.Clinical pharmacology and therapeutics · 2012Trial
- Predicting the toxicity of weekly docetaxel in advanced cancer.Clinical pharmacokinetics · 2006Trial
- Optimizing First-Line Therapeutics in Non-Small Cell Lung Cancer: Insights From Joint Modeling and Large-Scale Data Analysis.CPT: pharmacometrics & systems pharmacology · 2025Article
- A Cross-sectional Comparative Analysis of Eleven Population Pharmacokinetic Models for Docetaxel in Chinese Breast Cancer Patients.Current drug metabolism · 2024Article
- Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas.Neuro-oncology · 2023Article
- A pharmacometrics model to define docetaxel target in early breast cancer.British journal of clinical pharmacology · 2023Article
- Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study.Pharmaceutical research · 2019Article
- Survival Prolongation Index as a Novel Metric to Assess Anti-Tumor Activity in Xenograft Models.The AAPS journal · 2019Article
- Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach.European journal of clinical pharmacology · 2016Article
- Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer.Cancers · 2016Article
- Docetaxel induces moderate ovarian toxicity in mice, primarily affecting granulosa cells of early growing follicles.Molecular human reproduction · 2014Article
- Breath tests to phenotype drug disposition in oncology.Clinical pharmacokinetics · 2013Review
- Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.Pharmacogenomics · 2013Article
- Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2012Article
- Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology.British journal of clinical pharmacology · 2012Review
- Covariate pharmacokinetic model building in oncology and its potential clinical relevance.The AAPS journal · 2012Review
- Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.Breast cancer research and treatment · 2011Article
- Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements.Clinical pharmacology and therapeutics · 2008Article
- Clinical pharmacology of cancer therapies in older adults.British journal of cancer · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsPrevious pharmacokinetic studies of the 3-weekly regimen (100 mg m(-2) every 3 weeks) of docetaxel have shown that docetaxel clearance is affected by liver function, body surface area, age, serum alpha1-acid glycoprotein and cytochrome P450 3A4 (CYP3A4) activity. However, the pharmacokinetics of a weekly docetaxel (40 mg m(-2) week(-1)) schedule are not well characterized. The aims of this study were (a) to investigate the pharmacokinetics of docetaxel (40 mg m(-2) week(-1)) using sparse concentration-time data collected from patients with advanced cancer and (b) to utilize a population pharmacokinetic approach to identify patient covariates that significantly influence the clearance of docetaxel when administered according to this regimen.
methodsA two-compartment pharmacokinetic model was used to describe the docetaxel concentration-time data from 54 patients with advanced cancer. The mean population and individual posterior Bayesian estimates of docetaxel clearance were estimated using P-PHARM. The relationships between docetaxel clearance and 21 covariates were investigated. This included estimates of CYP3A4 function in each patient using the erythromycin breath test (1/tmax). Significant covariates were included into the final population pharmacokinetic model. Pharmacokinetic models were validated using a data splitting approach with a dataset consisting of 16 patients.
resultsSignificant relationships were found between docetaxel clearance and 1/tmax (erythromycin breath test parameter) and several of the liver function enzymes and CL was best described by the equation; CL = 21.51 + 217 (1/tmax) - 0.13 (ALT). This final population pharmacokinetic model provided both precise and unbiased predictions of docetaxel concentrations in a validation group of patients and an estimate of the population mean (95% confidence interval) clearance of docetaxel was 30.13 l h(-1) (12.54, 46.04 l h(-1)) with an intersubject variability 30%.
conclusionsA population pharmacokinetic model has been developed and validated for weekly docetaxel (40 mg m(-2)) in patients with advanced cancer. These results indicate that CYP3A4 activity and hepatic function have an impact on the pharmacokinetics of docetaxel when administered weekly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.